Elber S. Camacho

1.2k total citations
24 papers, 929 citations indexed

About

Elber S. Camacho is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Elber S. Camacho has authored 24 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Hematology and 11 papers in Oncology. Recurrent topics in Elber S. Camacho's work include Multiple Myeloma Research and Treatments (12 papers), Protein Degradation and Inhibitors (11 papers) and Nausea and vomiting management (4 papers). Elber S. Camacho is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Protein Degradation and Inhibitors (11 papers) and Nausea and vomiting management (4 papers). Elber S. Camacho collaborates with scholars based in United States, South Africa and Germany. Elber S. Camacho's co-authors include Marti McKinley, Sundar Jagannath, David Irwin, John Crowley, Jeffrey L. Wolf, Amitabha Mazumder, Jose Lutzky, Brian G.M. Durie, Eli Gabayan and David P. Schenkein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Elber S. Camacho

24 papers receiving 904 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elber S. Camacho United States 11 474 444 440 210 202 24 929
Oluwatoyin Shonukan United States 10 286 0.6× 355 0.8× 266 0.6× 124 0.6× 83 0.4× 18 683
H Weinstein United States 13 199 0.4× 158 0.4× 133 0.3× 290 1.4× 80 0.4× 24 720
Hong Xie United States 13 406 0.9× 338 0.8× 252 0.6× 59 0.3× 54 0.3× 29 739
Shulamiet Wittebol Netherlands 15 319 0.7× 384 0.9× 493 1.1× 166 0.8× 159 0.8× 33 791
Daniela Graziani Italy 11 393 0.8× 284 0.6× 51 0.1× 184 0.9× 64 0.3× 23 767
Marise Weil France 6 194 0.4× 250 0.6× 234 0.5× 118 0.6× 48 0.2× 10 591
Unn‐Merete Fagerli Norway 13 278 0.6× 286 0.6× 261 0.6× 201 1.0× 138 0.7× 33 744
Mei Dong China 14 379 0.8× 241 0.5× 46 0.1× 442 2.1× 68 0.3× 49 775
Brigitte Kolb France 9 238 0.5× 373 0.8× 426 1.0× 243 1.2× 208 1.0× 25 728
Izilda Aparecida Cardinalli Brazil 17 191 0.4× 277 0.6× 43 0.1× 66 0.3× 98 0.5× 54 683

Countries citing papers authored by Elber S. Camacho

Since Specialization
Citations

This map shows the geographic impact of Elber S. Camacho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elber S. Camacho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elber S. Camacho more than expected).

Fields of papers citing papers by Elber S. Camacho

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elber S. Camacho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elber S. Camacho. The network helps show where Elber S. Camacho may publish in the future.

Co-authorship network of co-authors of Elber S. Camacho

This figure shows the co-authorship network connecting the top 25 collaborators of Elber S. Camacho. A scholar is included among the top collaborators of Elber S. Camacho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elber S. Camacho. Elber S. Camacho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morris, Devin, et al.. (2019). An unusual case of primary acinar cell carcinoma of the liver and its treatment. Journal of Gastrointestinal Oncology. 10(5). 1021–1026. 3 indexed citations
2.
Jordan, Karin, Stuart A. Green, Elber S. Camacho, et al.. (2018). Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. Supportive Care in Cancer. 26(11). 3773–3780. 7 indexed citations
3.
Jordan, Karin, et al.. (2016). Exploration of the heterogeneity of moderately emetogenic chemotherapy on response to fosaprepitant in a randomized phase 3 trial. Annals of Oncology. 27. vi497–vi497. 3 indexed citations
4.
5.
6.
Bensinger, William, Sundar Jagannath, Robert Vescio, et al.. (2009). Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. British Journal of Haematology. 148(4). 562–568. 19 indexed citations
7.
Jagannath, Sundar, Brian G.M. Durie, Jeffrey L. Wolf, et al.. (2009). Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. British Journal of Haematology. 146(6). 619–626. 37 indexed citations
8.
Bensinger, William, Sundar Jagannath, Robert Vescio, et al.. (2008). A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma. Blood. 112(11). 94–94. 20 indexed citations
9.
Friedberg, Jonathan W., Philip Cohen, Ling Chen, et al.. (2008). Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study. Journal of Clinical Oncology. 26(2). 204–210. 236 indexed citations
10.
Jagannath, Sundar, Brian G.M. Durie, Jeffrey L. Wolf, et al.. (2006). Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.. Blood. 108(11). 796–796. 32 indexed citations
11.
Jagannath, Sundar, Brian G.M. Durie, Jeffrey L. Wolf, et al.. (2005). Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology. 129(6). 776–783. 299 indexed citations
12.
Jagannath, Sundar, Jeffrey L. Wolf, Elber S. Camacho, et al.. (2005). Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma.. Blood. 106(11). 783–783. 14 indexed citations
13.
14.
Jagannath, Sundar, Jeffrey L. Wolf, Elber S. Camacho, et al.. (2004). A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.. Blood. 104(11). 333–333. 19 indexed citations
15.
Jahanzeb, Mohammad, et al.. (2004). Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study.. PubMed. 24(2C). 1239–42. 9 indexed citations
16.
Jagannath, Sundar, Jeffrey L. Wolf, Elber S. Camacho, et al.. (2004). First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM). Journal of Clinical Oncology. 22(14_suppl). 6551–6551. 3 indexed citations
17.
Wilbur, D. W., et al.. (1987). Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas--a prospective, randomized study.. Journal of Clinical Oncology. 5(2). 278–285. 54 indexed citations
18.
Camacho, Elber S., et al.. (1984). Tamoxifen response following no response to orchiectomy in metastatic male breast cancer: A case report. Journal of Surgical Oncology. 25(1). 42–43. 8 indexed citations
19.
Camacho, Elber S., Carl Pinsky, David W. Braun, et al.. (1981). DNCB reactivity and prognosis in 419 patients with malignant melanoma. Cancer. 47(10). 2446–2450. 8 indexed citations
20.
Budman, Daniel R., Elber S. Camacho, & Robert E. Wittes. (1978). The current causes of death in patients with malignant melanoma. European Journal of Cancer (1965). 14(4). 327–330. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oluwatoyin Shonukan Breakdown of academic impact, for papers by H Weinstein Breakdown of academic impact, for papers by Hong Xie Breakdown of academic impact, for papers by Shulamiet Wittebol Breakdown of academic impact, for papers by Daniela Graziani Breakdown of academic impact, for papers by Marise Weil Breakdown of academic impact, for papers by Unn‐Merete Fagerli Breakdown of academic impact, for papers by Mei Dong Breakdown of academic impact, for papers by Brigitte Kolb Breakdown of academic impact, for papers by Izilda Aparecida Cardinalli
Rankless by CCL
2026